CD Biosynsis provides a comprehensive suite of HeLa Cells Genome Editing & Metabolic Engineering Solutions, designed to transform the world's most famous immortalized human cell line into a high-performance chassis for biomedical research and bioproduction. Despite their genomic complexity and aneuploidy, HeLa cells remain an indispensable model for cancer biology, virology, and drug discovery. Our platform integrates precision tools like CRISPR-Cas9, Base Editing, and CRISPRi with advanced metabolic modeling to achieve definitive gene knockouts, site-specific knock-ins, and optimized metabolic flux. We empower researchers to bypass the traditional "trial and error" approach, delivering genetically stable, monoclone-verified HeLa strains tailored for high-throughput screening and complex human protein expression.
Get a QuoteHeLa cells are hyper-triploid and genetically unstable, which often results in phenotypic drift and inconsistent experimental data. Our metabolic engineering solutions address these challenges by applying rigorous systems biology principles to the HeLa chassis. By mapping the intracellular metabolic flux and signaling networks, we identify specific genetic targets that can be modified to enhance cell fitness, stabilize reporter expression, or humanize glycosylation patterns for protein production. This integrated approach ensures that every genetic modification is functionally validated, providing a reliable and reproducible human cell model for advanced pharmaceutical and academic research.
Precise manipulation of the HeLa genome using CRISPR-Cas9, Base Editing, and Prime Editing to create stable knockouts (KO) and site-specific knock-ins (KI).
Rational re-engineering of signal transduction and metabolic pathways to enhance cell performance, drug sensitivity, or viral production efficiency.
Utilizing engineered HeLa strains for the production of complex human proteins with authentic post-translational modifications (PTMs).
Accelerated development of customized HeLa cell lines through automated high-throughput screening (HTS) and monoclonal selection.
Simultaneous inactivation of multiple redundant genes or parallel pathways to dissect complex phenotypes in aneuploid HeLa backgrounds.
Integrating omics data with computational systems biology to model cellular behavior and validate drug targets in a predictive framework.
Our systematic approach ensures that every engineered HeLa strain meets the highest standards of genetic stability and functional performance.
1. In Silico Design & Modeling
2. Precision Genetic Engineering
3. High-Throughput Screening
4. Functional Validation & Bank Delivery
Establish a baseline metabolic/signaling model of the host HeLa line. Identify optimal gRNA targets and simulate the impact of proposed edits on the cellular network.
Perform multiplex genome editing using RNP delivery to minimize off-target effects. Achieve multi-allelic disruption to overcome hyper-triploidy.
Validate the engineered phenotype through secondary assays (e.g., Western Blot, viral entry). Confirm stability over 30+ passages and deliver the Master Cell Bank.
Aneuploidy Mastery
Dedicated expertise in handling the hyper-triploid HeLa genome, ensuring 100% allelic disruption for definitive functional knockouts.
Predictive Modeling
Our computational models allow for in silico testing, significantly reducing the timeline and cost of metabolic pathway optimization.
Site-Specific Fidelity
Focus on site-specific knock-in into validated "safe harbor" loci avoids the gene silencing common in random integration.
Data-Driven Quality
Every strain is delivered with extensive validation data, including NGS genotyping, phenotypic characterization, and growth stability metrics.
1. How do you ensure a complete knockout in a hyper-triploid HeLa cell?
We use multiple gRNAs per gene and high-concentration RNP delivery. Successful multi-allelic KO is verified by Next-Generation Sequencing (NGS) to confirm 100% frameshift mutation frequency across all chromosome copies.
2. Can you optimize HeLa cells for serum-free suspension growth?
Yes. We apply metabolic engineering to target lipid metabolism and utilize adaptive evolution combined with high-throughput screening to transition adherent lines to robust suspension growth.
3. What is the typical success rate for large gene knock-ins in HeLa?
By using CRISPR/HDR in combination with specialized small-molecule enhancers, we achieve high-efficiency integration of large cassettes (e.g., reporters or human pathways) into genomic safe harbors like AAVS1.
4. How does metabolic modeling benefit pathway optimization?
Modeling allows us to perform Flux Balance Analysis (FBA) to predict metabolic bottlenecks. This identifies which genes to overexpress or delete to maximize specific cellular functions without harming viability.
5. What Post-Translational Modifications (PTMs) are preserved in HeLa expression systems?
As a human host, HeLa cells provide authentic human-specific glycosylation, phosphorylation, and proteolytic processing, which are often essential for the biological activity of therapeutic proteins.
6. Do you offer multiplex gene editing for multi-pathway engineering?
Yes. Our platform supports simultaneous editing of multiple loci, allowing for the disruption of parallel signaling pathways or the assembly of complex multi-enzyme metabolic routes in a single workflow.
7. How is the genetic stability of the modified strains verified?
We perform long-term culture stability tests (up to 50 passages) followed by targeted sequencing and functional assays to ensure the genetic modification and resulting phenotype remain constant over time.
8. What type of screening data is provided in the final report?
Reports include NGS sequencing results, single-cell cloning proof (monoclonality), Western Blot or flow cytometry data for functional verification, and growth curve analysis of the final strain.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
|
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.